Correction to: CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy
- PDF / 544,617 Bytes
- 1 Pages / 595.276 x 790.866 pts Page_size
- 13 Downloads / 186 Views
Cancer Cell International Open Access
CORRECTION
Correction to: CRISPR‑Cas, a robust gene‑editing technology in the era of modern cancer immunotherapy Seyed Mohammad Miri1, Elham Tafsiri2, William Chi Shing Cho3 and Amir Ghaemi1*
Correction to: C ancer Cell Int (2020) 20:456 https://doi.org/10.1186/s12935-020-01546-8
Following publication of the original article [1], we were notified the Department of Virology, Pasteur Institute of Iran should have been mentioned as the only affiliation for the first and last author. The revised affiliation is reflected in this correction article. Author details 1 Department of Virology, Pasteur Institute of Iran, Tehran, Iran. 2 Molecular Medicine Department, Pasteur Institute of Iran, Biotechnology Research
Center, Tehran, Iran. 3 Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China.
Reference 1. Miri SM, et al. CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy. Caner Cell Int. 2020;20:456. https://doi. org/10.1186/s12935-020-01546-8.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original article can be found online at https://doi.org/10.1186/s1293 5-020-01546-8. *Correspondence: [email protected]; [email protected] 1 Department of Virology, Pasteur Institute of Iran, Tehran, Iran Full list of author information is available at the end of the article © The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Data Loading...
